Wedbush Reaffirms “Outperform” Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a report released on Thursday,RTT News reports. They currently have a $7.00 target price on the stock.

Other equities analysts also recently issued reports about the stock. JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $17.50 target price on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Vor Biopharma has an average rating of “Buy” and an average price target of $10.79.

Vor Biopharma Stock Performance

Shares of NYSE:VOR traded up $0.01 during midday trading on Thursday, hitting $0.85. The company’s stock had a trading volume of 242,997 shares, compared to its average volume of 593,730. The business’s 50 day simple moving average is $1.25 and its 200 day simple moving average is $1.01. The company has a market cap of $58.51 million, a P/E ratio of -0.52 and a beta of -0.40. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $2.43.

Institutional Trading of Vor Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of VOR. Two Sigma Investments LP raised its position in Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock worth $181,000 after buying an additional 25,930 shares during the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Vor Biopharma in the fourth quarter worth $33,000. Northern Trust Corp raised its position in Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after acquiring an additional 44,252 shares in the last quarter. Virtu Financial LLC purchased a new position in Vor Biopharma in the fourth quarter worth $60,000. Finally, XTX Topco Ltd purchased a new position in Vor Biopharma in the fourth quarter worth $80,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.